Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres

Vaccine ◽  
1996 ◽  
Vol 14 (17-18) ◽  
pp. 1677-1685 ◽  
Author(s):  
Y TABATA
2019 ◽  
Vol 39 (3) ◽  
Author(s):  
Jialu Wang ◽  
Lulu Huang ◽  
Chunxiao Mou ◽  
En Zhang ◽  
Yongheng Wang ◽  
...  

Abstract Porcine epidemic diarrhea (PED) is a highly contagious disease in newborn piglets and causes substantial economic losses in the world. PED virus (PEDV) spreads by fecal–oral contact and can be prevented by oral immunization. Therefore, it is necessary to develop an effective oral vaccine against PEDV infection. Currently, Bacillus subtilis as recombinant vaccine carrier has been used for antigen delivery and proved well in immune effect and safety. The present study evaluated the immunogenicity of recombinant Bacillus subtilis (B. subtilis-RC) in piglets via oral administration. After oral immunization in piglets, B. subtilis-RC significantly increased the local mucosal immune responses. Oral administration with B. subtilis-RC significantly improved the level of specific mucosal immunoglobulin A (IgA) antibodies against PEDV infection, through enlarging the area of Peyer’s patches (PPs) and increasing the number of ileum IgA+ secreting (SIgA) cells. In the meantime, B. subtilis-RC remarkably increased the number of intraepithelial lymphocytes (IELs). We also observed that oral administration of B. subtilis-RC significantly increased CD3+T lymphocytes’ numbers and up-regulated the ratio of CD4+/CD8+ T cells. Furthermore, high titers of specific serum immunoglobulin G (IgG) revealed satisfactory systemic immune response against PEDV infection. In summary, our study demonstrated that oral administration of B. subtilis-RC could trigger a high level of local and systemic immune responses and would be a promising candidate vaccine against PEDV infection in piglets.


1993 ◽  
Vol 36 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Yoshimine Fujii ◽  
Yukihiko Aramaki ◽  
Toshifumi Hara ◽  
Kiyoto Yachi ◽  
Hiroshi Kikuchi ◽  
...  

2018 ◽  
Vol 102 (24) ◽  
pp. 10703-10711 ◽  
Author(s):  
Keita Takahashi ◽  
Ayumu Yano ◽  
Shiori Watanabe ◽  
Philippe Langella ◽  
Luis G. Bermúdez-Humarán ◽  
...  

2021 ◽  
Vol 9 (4) ◽  
pp. 683
Author(s):  
Julio Villena ◽  
Chang Li ◽  
Maria Guadalupe Vizoso-Pinto ◽  
Jacinto Sacur ◽  
Linzhu Ren ◽  
...  

The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms involved in the improvement of mucosal antiviral defenses by beneficial Lactiplantibacillus plantarum strains, (b) the systems for the expression of heterologous proteins in L. plantarum and (c) the successful expressions of viral antigens in L. plantarum that were capable of inducing protective immune responses in the gut and the respiratory tract after their oral administration. The ability of L. plantarum to express viral antigens, including the spike protein of SARS-CoV-2 and its capacity to differentially modulate the innate and adaptive immune responses in both the intestinal and respiratory mucosa after its oral administration, indicates the potential of this LAB to be used in the development of a mucosal COVID-19 vaccine.


Sign in / Sign up

Export Citation Format

Share Document